ReviewAnnals of translational medicine2014
microRNAs and cancer metabolism reprogramming: the paradigm of metformin.
Review in Annals of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metformin's Modulatory Effects on miRNAs Function in Cancer Stem Cells-A Systematic Review.Cells · 2020Pooled it
- Monitoring Vitamin BNutrients · 2019Trial
- Metformin and its Nanoformulations in Cancer Prevention and Therapy.Current pharmaceutical design · 2025Review
- Metformin as a potential agent for modulating the faulty endometriotic mesenchymal stem cells: A case-control study.International journal of reproductive biomedicine · 2022Article
- The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.International journal of cancer · 2022Review
- The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases.Inflammopharmacology · 2022Review
- Metformin - a new approach.Pediatric endocrinology, diabetes, and metabolism · 2021Review
- Review
- Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells.Cancers · 2020Review
- Article
- Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes.Frontiers in oncology · 2020Article
- Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.Biomolecules · 2019Review
- Metformin and Breast Cancer: Molecular Targets.Journal of mammary gland biology and neoplasia · 2019Review
- Reprogramming of CaCo2 colorectal cancer cells after using the complex of poly-(N-vinylpyrrolidone) with small non-coding RNAs.Toxicology reports · 2019Article
- Potential application of cell reprogramming techniques for cancer research.Cellular and molecular life sciences : CMLS · 2019Review
- Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment.Frontiers in physiology · 2018Review
- Long non-coding RNA CRYBG3 regulates glycolysis of lung cancer cells by interacting with lactate dehydrogenase A.Journal of Cancer · 2018Article
- Therapeutic strategies against cancer stem cells in human colorectal cancer.Oncology letters · 2017Article
- Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression.Journal of Cancer · 2017Article
- Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction.Molecular genetics and genomics : MGG · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence witnesses that cancer metabolism alterations represent a critical hallmark for many types of human tumors. There is a strong need to understand and dissect the molecular mechanisms underlying cancer metabolism to envisage specific biomarkers and underpin critical molecular components that might represent novel therapeutic targets. One challenge, that is the focus of this review, is the reprogramming of the altered metabolism of a cancer cell toward that of un-transformed cell. The anti-hyperglicemic agent, metformin has proven to be effective in reprogramming the metabolism of cancer cells even from those subpopulations endowed with cancer stem like features and very high chemoresistenace to conventional anticancer treatments. A functional interplay involving selective modulation of microRNAs (miRNAs) takes place along the anticancer metabolic effects exerted by metformin. The implications of this interplay will be also discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.